The next decade of medicine will be defined by breakthrough medicines and their quick delivery to patients.

• Novartis is working to ensure both happen in the United States, strengthening outcomes for patients, creating jobs and driving progress in communities nationwide.

Here's the deal: Novartis plans to invest $23 billion over the next five years, creating more than 1,000 jobs and supporting 4,000 more across the U.S. supply chain.

• This investment will expand Novartis' coast-to-coast U.S. manufacturing and R&D footprint, enabling the company to develop key medicines end-to-end across all its therapeutic areas on American soil for the first time.

The result: More jobs, a stronger supply chain and bringing breakthrough therapies closer to patients in the communities they call home.

Why it's important: The reliable access to medicines depends on strong supply chains, underpinned by robust American manufacturing.

• By localizing manufacturing, from research to packaging, Novartis is building greater predictability into how treatments are manufactured and delivered.

The strategy: Novartis will expand its R&D and manufacturing network to a total of 10 facilities — adding seven brand-new sites — across California, New Jersey, Indiana, Massachusetts, Florida, Texas and North Carolina.

• The plan includes a new R&D hub in California, a flagship manufacturing hub in North Carolina, two specialized radioligand therapy (RLT) plants in Florida and Texas and a soon-to-be-announced additional new manufacturing site.

The impact: This investment will strengthen the reliability, speed and resilience of Novartis' U.S. supply chain, ensuring that innovation reaches patients faster and with fewer disruptions.

• That includes RLT, a breakthrough approach to cancer care that targets tumor cells while limiting damage to healthy tissue.
• Worth a mention: As the only company with a commercial RLT portfolio, Novartis is pioneering the next era of cancer treatment, localizing manufacturing to maintain an on-time delivery rate of 99.5% so patients receive this time-sensitive treatment exactly when it's needed.

Key numbers:

• Nearly 1,000 new Novartis roles and 4,000 additional U.S. jobs across the supply chain.

• The construction of two new sites and a major expansion of an existing facility in North Carolina, bringing the total operational footprint in the state to over 700,000 square feet.
• 450,000 square feet of new laboratory and office space in San Diego, home to the company's second-largest US research hub.

What Novartis is saying: "By bringing research, development and manufacturing closer to patients and communities in the U.S., we're building a future-ready supply chain that unlocks new possibilities for care," said Victor Bultó, U.S. President, Novartis.

• "I'm proud of the progress we've made toward delivering on our commitment to manufacture all our key medicines end-to-end in the U.S., while creating U.S. jobs and growing the U.S. economy."

Looking ahead: This investment cements Novartis' long-term commitment to manufacturing breakthrough treatments in the U.S. across its main therapeutic areas, including cancer, immune disorders, neurological conditions and heart and metabolic diseases.

The takeaway: With $23 billion in investment over the next five years and a coast-to-coast network of researchers, engineers and manufacturing associates, Novartis is redefining what it means to invest in America's health.

Learn more about the investment.